Juno Therapeutics Inc. (JUNO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO)

JUNO 86.96

0.0%

Mar 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (57)	3/2/2017 8:16:00 AM
From: Biotech Jim	Read Replies (1) of 84

Trying to pick up shares pre-market, but no many sellers. Very interesting conf call. Lots going on. Three keys to CRS and tox with JCAR017 (NHL and CLL could be first approvals, pretty good data with JCAR017): Extent of early T cell clonal expansion due to 3 factors (extensively explored), and are directly causative to side effects of CRS, neurotox, and cerebral edema. 1. Treatments prior to cell infusion 2. Potential patient specific factors 2. Engineered construct and specific transduced T cell characteristics, ie product characteristics. I am trying to buy some more JUNO this am, my orders are hidden but they are lower than current bids.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next